KIORA PHARMACEUTICALS, INC. Stock Split Ratio
KIORA PHARMACEUTICALS, INC. (KPRX) had Stock Split Ratio of 11.11% as of 2024-06-11, per its 10-Q filed 2025-05-09.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-03-25
- 2024-06-11: Stockholders' Equity Note, Stock Split, Conversion Ratio 11.11%.
- 2024-06-06: Stockholders' Equity Note, Stock Split, Conversion Ratio 11.10%.
- 2022-09-27: Stockholders' Equity Note, Stock Split, Conversion Ratio 2.50%.
- 2019-08-30: Stockholders' Equity Note, Stock Split, Conversion Ratio 6.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2024-06-11 | 11.11% 10-Q · filed 2025-05-09 |
| 2024-06-06 | 11.10% 10-K · filed 2026-03-25 |
| 2022-09-27 | 2.50% 10-K · filed 2025-03-25 |
| 2019-08-30 | 6.00% 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |